Since 2008, our computationally-driven biomarker development process has generated blood test content for more than 15 indications in heart failure, chronic lung disease, kidney disease, and organ transplantation. We have also used our end-to-end approach from clinical need to clinical implementation to provide services to organizations seeking biomarker development expertise in various other disease indications.

Our suite of biomarker services and multidisciplinary team have supported academic investigators, clinicians, research institutions, biotechnology and diagnostic companies, and pharmaceutical companies, and formed large collaborative networks across the globe.

Click here to learn more about ourĀ Computational Services.